163 related articles for article (PubMed ID: 38031670)
1. Cardiac Magnetic Resonance Imaging Findings in Human Epidermal Growth Factor Receptor 2-Targeted Therapy-Related Cardiotoxicity.
Şener YZ; Ardalı Düzgün S; Hazırolan T; Tokgözoğlu L
Anatol J Cardiol; 2023 Dec; 27(12):E38-E39. PubMed ID: 38031670
[No Abstract] [Full Text] [Related]
2. Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies.
Florido R; Smith KL; Cuomo KK; Russell SD
J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28939718
[No Abstract] [Full Text] [Related]
3. Cardiac imaging in cardiotoxicity: a focus on clinical practice.
Makavos G; Ikonomidis I; Palios J; Rigopoulos A; Katogiannis K; Parissis J; Paraskevaidis I; Noutsias M
Heart Fail Rev; 2021 Sep; 26(5):1175-1187. PubMed ID: 32306221
[TBL] [Abstract][Full Text] [Related]
4. The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review.
Wu Q; Bai B; Tian C; Li D; Yu H; Song B; Li B; Chu X
Cardiovasc Drugs Ther; 2022 Jun; 36(3):511-524. PubMed ID: 33847848
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics.
Hervent AS; De Keulenaer GW
Int J Mol Sci; 2012 Sep; 13(10):12268-86. PubMed ID: 23202898
[TBL] [Abstract][Full Text] [Related]
6. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
[TBL] [Abstract][Full Text] [Related]
7. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
de Korte MA; de Vries EG; Lub-de Hooge MN; Jager PL; Gietema JA; van der Graaf WT; Sluiter WJ; van Veldhuisen DJ; Suter TM; Sleijfer DT; Perik PJ
Eur J Cancer; 2007 Sep; 43(14):2046-51. PubMed ID: 17719768
[TBL] [Abstract][Full Text] [Related]
8. Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice.
Bouwer NI; Jager A; Liesting C; Kofflard MJM; Brugts JJ; Kitzen JJEM; Boersma E; Levin MD
Breast; 2020 Aug; 52():33-44. PubMed ID: 32361151
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.
Dent SF; Morse A; Burnette S; Guha A; Moore H
Curr Oncol Rep; 2021 Aug; 23(11):128. PubMed ID: 34453232
[TBL] [Abstract][Full Text] [Related]
10. Update on cardiotoxicity of anti-cancer treatments.
Rosa GM; Gigli L; Tagliasacchi MI; Di Iorio C; Carbone F; Nencioni A; Montecucco F; Brunelli C
Eur J Clin Invest; 2016 Mar; 46(3):264-84. PubMed ID: 26728634
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity of HER2-targeted therapies.
Copeland-Halperin RS; Liu JE; Yu AF
Curr Opin Cardiol; 2019 Jul; 34(4):451-458. PubMed ID: 31082851
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of left atrial remodeling using cardiovascular magnetic resonance imaging in breast cancer patients treated with adjuvant trastuzumab.
Huang F; Brezden-Masley C; Chan KKW; Barfett JJ; Kirpalani A; Deva DP; Jimenez-Juan L; Barthur A; Song L; Chacko B; Ng MY; Connelly K; Wong KCK; Yan AT
Eur Radiol; 2022 Jun; 32(6):4234-4242. PubMed ID: 34993574
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.
Schneider JW; Chang AY; Rocco TP
Semin Oncol; 2001 Oct; 28(5 Suppl 16):18-26. PubMed ID: 11706392
[TBL] [Abstract][Full Text] [Related]
14. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
Litvak A; Batukbhai B; Russell SD; Tsai HL; Rosner GL; Jeter SC; Armstrong D; Emens LA; Fetting J; Wolff AC; Silhy R; Stearns V; Connolly RM
Cancer; 2018 May; 124(9):1904-1911. PubMed ID: 29381193
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy.
Cheng S; Wang J; Wang Y; Qi L; Li F; Liu J; Chen J; Fan Y; Xie L
Eur Radiol Exp; 2023 May; 7(1):22. PubMed ID: 37183212
[TBL] [Abstract][Full Text] [Related]
16. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
Fallah-Rad N; Walker JR; Wassef A; Lytwyn M; Bohonis S; Fang T; Tian G; Kirkpatrick ID; Singal PK; Krahn M; Grenier D; Jassal DS
J Am Coll Cardiol; 2011 May; 57(22):2263-70. PubMed ID: 21616287
[TBL] [Abstract][Full Text] [Related]
17. Early diagnosis of chemotherapy-induced cardiotoxicity by cardiac MRI.
Cau R; Bassareo P; Cherchi V; Palmisano V; Suri JS; Porcu M; Balestrieri A; Pontone G; Saba L
Eur J Radiol; 2020 Sep; 130():109158. PubMed ID: 32652404
[TBL] [Abstract][Full Text] [Related]
18. Antiblastic drug-induced cardiotoxicity and cardioprotection: a compendium.
Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e1-e2. PubMed ID: 27755236
[No Abstract] [Full Text] [Related]
19. Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity: cardiovascular magnetic resonance and nuclear cardiology.
Pepe A; Pizzino F; Gargiulo P; Perrone-Filardi P; Cadeddu C; Mele D; Monte I; Novo G; Zito C; Di Bella G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e45-e54. PubMed ID: 27755242
[TBL] [Abstract][Full Text] [Related]
20. Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition.
Stuhlmiller TJ; Zawistowski JS; Chen X; Sciaky N; Angus SP; Hicks ST; Parry TL; Huang W; Beak JY; Willis MS; Johnson GL; Jensen BC
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29051215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
